
    
      Assess efficacy of FDC vs. ezetimibe vs. placebo for 12 week LDL-C lowering, changes in
      atherogenic lipids, hsCRP and exploratory glycemic measures as well as safety in patients
      with type 2 diabetes and elevated LDL-C.
    
  